Strata Skin Sciences (Strata Skin Sciences) Debt-to-Equity

: 1.23 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Strata Skin Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.35 Mil. Strata Skin Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.28 Mil. Strata Skin Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12.69 Mil. Strata Skin Sciences's debt to equity for the quarter that ended in Dec. 2023 was 1.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Strata Skin Sciences's Debt-to-Equity or its related term are showing as below:

SSKN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.41 Max: 1.62
Current: 1.23

During the past 13 years, the highest Debt-to-Equity Ratio of Strata Skin Sciences was 1.62. The lowest was 0.24. And the median was 0.41.

SSKN's Debt-to-Equity is ranked worse than
90.74% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs SSKN: 1.23

Strata Skin Sciences Debt-to-Equity Historical Data

The historical data trend for Strata Skin Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.30

0.42

0.32

0.39

1.23

Strata Skin Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.39	0.43	0.93	0.97	1.23

Competitive Comparison

For the Medical Devices subindustry, Strata Skin Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Skin Sciences Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Debt-to-Equity falls into.

Strata Skin Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Strata Skin Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.352	+	15.281)	/	12.688
	=	1.23

Strata Skin Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.352	+	15.281)	/	12.688
	=	1.23

Strata Skin Sciences (NAS:SSKN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Strata Skin Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Strata Skin Sciences (Strata Skin Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

E2OM:Germany E2OM:Germany

Address

5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website

https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

Executives

Shmuel Gov	officer: SVP & General Manager Carlsbad	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein	director	5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc.	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp	10 percent owner	590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz	officer: Chief Financial Officer	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia	director, officer: Chief Executive Officer	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang	director	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727